MagnetisMM-15

Elranatamab Post Trial Access: An Open-Label, Single-Arm Study For Participants with Multiple Myeloma Continuing From Pfizer-Sponsored Elranatamab Clinical Studies

What's the purpose of the trial?

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Trial status

Not yet accepting

Phase
Phase 4
Enrollment
72
Last Updated
2 weeks ago
Patient Screener

Participating Centers

There are 2 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Elranatamab is a B-Cell Maturation Antigen (BCMA) CD-3 bispecific antibody being tested in multiple myeloma

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Not yet accepting

Elranatamab

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.